Company Announcements

Evotec Appoints Dr Christian Wojczewski as CEO: Implications for the CDMO Sector

Evotec SE’s appointment of Dr Christian Wojczewski as CEO offers strategic direction for its CDMO services, impacting manufacturing capacity, outsourcing trends and market positioning.

December 26, 2025

Company Announcements

Evotec and Variant Bio Strategic Partnership: Implications for the CDMO Sector

Explore how the recent collaboration between Evotec and Variant Bio to develop fibrosis treatments creates opportunities and challenges for CDMOs in talent, capacity, supply…

December 26, 2025

Company Announcements

Evotec SE to Announce Fiscal Year 2023 Results: What the Pharma CDMO Sector Needs to Know

Evotec SE will release its 2023 financial results on April 24, 2024. CDMO stakeholders should assess the outcomes for insights on outsourcing demand, manufacturing…

December 25, 2025

Company Announcements

Evotec Appoints Aurélie Dalbiez as Chief People Officer: Strengthening CDMO Talent and Growth

Aurélie Dalbiez joins Evotec as Chief People Officer on June 15, 2024, to enhance talent strategies, workforce capacity and organizational culture across the company’s…

December 25, 2025

Company Announcements

Etherna Appoints Shelly West as US Business Development Director: Implications for CDMO Partnerships

Etherna expands its CDMO offerings in the US by appointing Shelly West as Business Development Director, driving mRNA partnerships and GMP manufacturing growth.

December 25, 2025

Company Announcements

Exothera Launches Continuous-Batch RNA Manufacturing Platform in North America to Boost CDMO Capabilities

Exothera has extended its world-first continuous-batch RNA manufacturing solution into North America, offering CDMOs automated, integrated production to accelerate clinical timelines, enhance yield and…

December 25, 2025

Company Announcements

Breakpoint Therapeutics Nominates BTX-011 Development Candidate: CDMO Outsourcing Implications

Breakpoint Therapeutics' nomination of BTX-011 highlights critical CDMO opportunities in process development, manufacturing and regulatory support for DDR-targeting oncology drugs.

December 25, 2025

Company Announcements

Tubulis’ €128M Series B2 Raise Spurs CDMO Growth for ADC Development

Tubulis’ €128 million Series B2 financing will fuel its solid tumor ADC pipeline and drive increased CDMO engagement in capacity expansion, outsourcing, and advanced…

December 24, 2025

Company Announcements

Evotec and Claris Ventures Partnership to Streamline CDMO-Driven Clinical Acceleration

Evotec SE and Claris Ventures launch a framework to streamline portfolio biotech programmes through an integrated CDMO platform, boosting manufacturing efficiency, regulatory alignment, and…

December 24, 2025

Company Announcements

Symbiosis Earns beMaster Plus Award and Its Implications for CDMO Exhibition Strategies

Symbiosis has been honored with the beMaster Plus award for build excellence in exhibition stand construction. This recognition offers key insights for CDMO companies…

December 24, 2025